Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2004

Filing Date
Filed March 9, 2005
Period End
December 31, 2004
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed March 9, 2005. Cited figures are marked; the original filing is the authoritative source.

Schering-Plough Corporation faced a challenging year in 2004, marked by a significant net loss of $947 milliona.

This downturn was largely attributed to the loss of market exclusivity for key products like CLARITIN and REBETOL, coupled with increased market competition and substantial special charges related to litigation and restructuring. Despite a slight decrease in overall net sales to $8.3 billionb, the company saw growth in specific segments like Animal Health and Consumer Health Care, and notable international sales increases for REMICADE. The company is actively pursuing a turnaround strategy under new leadership, focusing on key growth drivers such as the cholesterol franchise (VYTORIN and ZETIA) developed in partnership with Merck, and is seeking to improve financial stability through various means, including the repatriation of foreign earnings under the American Jobs Creation Act of 2004.

Key Highlights

  1. Schering-Plough reported a significant net loss of $947 million for the year ended December 31, 2004, a sharp decline from the previous year's loss of $92 million and a stark contrast to the $1.97 billion profit in 2002.
  2. Consolidated net sales saw a slight decrease of 1% to $8.27 billion in 2004, primarily driven by volume declines in the Prescription Pharmaceuticals segment, although offset by favorable foreign exchange rates.
  3. The Prescription Pharmaceuticals segment experienced a 3% sales decline to $6.42 billion, heavily impacted by the loss of exclusivity and increased competition for products like REBETOL (down 55%) and PEG-INTRON (down 30%).
  4. Significant special charges of $153 million were recorded in 2004, primarily related to employee termination costs ($119 million), compared to $599 million in 2003 which included substantial litigation reserves.
  5. The company is strategically investing in its cholesterol franchise, VYTORIN and ZETIA, through a joint venture with Merck, which contributed $1.2 billion in global sales in 2004, showing strong growth and becoming a key focus for future revenue.
  6. Schering-Plough is addressing compliance issues, including an ongoing consent decree with the FDA related to manufacturing practices, which has led to increased operating costs and reduced output.
  7. The company's financial strategy includes repatriating approximately $9.4 billion of unremitted foreign earnings under the American Jobs Creation Act of 2004, aimed at enhancing financial stability and funding U.S. operations.

Frequently Asked Questions

  1. What were the main drivers behind Schering-Plough's financial performance in 2004?

    Schering-Plough experienced a significant net loss in 2004 primarily due to the loss of market exclusivity for key drugs like CLARITIN and REBETOL, which led to substantial sales declines in those product lines. This was compounded by increased competition in the pharmaceutical market, especially in the hepatitis C franchise, and ongoing costs associated with manufacturing compliance efforts related to the FDA consent decree. The company also incurred special charges, though less than in the prior year.

  2. How did the joint venture with Merck for cholesterol drugs (VYTORIN and ZETIA) perform?

    The cholesterol franchise, developed through the joint venture with Merck, showed strong performance, generating $1.2 billion in global sales in 2004. VYTORIN and ZETIA are highlighted as key growth drivers for the company. Schering-Plough's equity income from this venture was $347 million in 2004, reflecting the growing contribution of these products.

  3. What is the status of the company's manufacturing compliance issues with the FDA?

    Schering-Plough remains under a consent decree with the FDA concerning current Good Manufacturing Practices (cGMP) at certain facilities. While the company is working to meet the decree's requirements, this has resulted in increased operational costs, reduced output, and has impacted R&D operations. The company is subject to potential payments if deadlines are missed and must complete revalidation programs for its products.

  4. How is Schering-Plough planning to improve its financial health?

    Schering-Plough is implementing a six- to eight-year 'Action Agenda' under new leadership to stabilize and turn around the company. Key strategies include focusing on the growth of its key products like VYTORIN and ZETIA, managing expenses, and leveraging the American Jobs Creation Act of 2004 to repatriate approximately $9.4 billion in foreign earnings. This repatriation is intended to provide greater financial stability and fund U.S. operations.